Taking Omeprazole Long Term? Here Is What the Research Actually Says
Over 73 million omeprazole prescriptions were issued in England in a single year. Millions more buy it over the counter without a second thought. It is one of the most used medicines in the UK and one of the least questioned. That is starting to change.
10 min read
What omeprazole actually does
Omeprazole belongs to a class of drugs called proton pump inhibitors (PPIs). It works by binding to the proton pumps in the stomach's lining and blocking them from producing acid. Less acid means less irritation of the oesophagus, less heartburn, and a reduction in the discomfort of conditions like GORD, gastritis, and stomach ulcers.
It does this very effectively. That effectiveness is precisely why it became one of the most prescribed drugs in the world. For short-term, supervised use, managing an active ulcer, protecting the stomach during a course of anti-inflammatories, allowing the oesophagus to recover, it has a clear clinical purpose.
What it does not do is address why the stomach was producing excess acid in the first place. It does not restore the mucosal layer that protects the stomach wall. It does not support the gut lining that was irritated or compromised. It reduces the symptom of excess acid and in doing so, it can allow the underlying conditions to remain unaddressed indefinitely.
"Omeprazole reduces the symptom of excess acid. The underlying gut lining — the actual foundation is never part of the equation."
The NHS warning most people have not read
If you buy omeprazole over the counter from a pharmacy, or increasingly online, the NHS guidance is explicit: do not take it for longer than two weeks without seeing a GP. After two weeks of OTC use without medical supervision, the NHS advises stopping and consulting a doctor if symptoms persist.
The reason is not that omeprazole is inherently dangerous in the short term. The reason is that taking it for longer without medical oversight can mask symptoms of more serious underlying conditions that need investigation. It can also lead to a dependency that makes stopping harder than expected.
Despite this guidance, research consistently shows that a significant proportion of people take PPIs continuously for months or years, often without regular medical review. A drug intended as a short-term bridge becomes a long-term fixture.
Between 2022 and 2023, over 73 million omeprazole prescriptions were dispensed in England, making it the single most prescribed drug in the NHS. An estimated 15 per cent of the UK population is taking a PPI at any given time, a significant proportion of whom are doing so long term and without regular clinical review. NHS omeprazole guidance
Effect 1
Stomach acid is not an enemy. It plays an essential role in breaking down food and enabling the absorption of key nutrients. When acid production is suppressed long term, the absorption of several critical micronutrients becomes impaired.
The most consistently documented are magnesium, vitamin B12, and iron. Low magnesium on PPIs is common enough that the NHS lists it explicitly as a known risk of long-term use. Magnesium deficiency presents as muscle cramps, fatigue, low mood, and poor sleep, symptoms that are rarely connected to the PPI by the person experiencing them.
Vitamin B12 deficiency is slower to develop but equally impactful when it does: brain fog, fatigue, nerve symptoms, and mood changes. B12 requires adequate stomach acid for absorption from food. With acid chronically suppressed, dietary B12 can pass through without being properly absorbed.
Iron absorption is similarly affected, a particular concern for people who are already borderline in their iron levels and experience unexplained fatigue while taking PPIs.
A systematic review of adverse gastrointestinal effects of long-term PPI use, published in 2025 in PMC, confirmed clear associations between prolonged PPI use and vitamin B12 deficiency, hypomagnesaemia, and impaired iron absorption particularly in older adults and those on continuous use exceeding 12 months. View source
Effect 2
One of the less discussed but increasingly well-documented effects of long-term PPI use is its impact on the composition of the gut microbiome. Stomach acid serves as a gatekeeping function: it destroys most bacteria that enter through food and drink before they reach the intestine. When that acid is significantly reduced, bacteria that would ordinarily be neutralised in the stomach pass through intact.
The result is a shift in microbial populations throughout the gastrointestinal tract. Studies using next-generation sequencing have consistently found that PPI users show significantly different microbiome profiles compared to non-users. Specifically, bacteria that normally reside in the mouth and throat including Streptococcaceae increase in abundance in the gut of PPI users, while beneficial bacteria including Bifidobacteriaceae and Lachnospiraceae decline.
This shift referred to as gut dysbiosis has downstream consequences for digestion, immunity, and gut lining integrity. The gut microbiome and the gut lining have a closely interdependent relationship. A dysbiotic microbiome creates a less hospitable environment for the lining to maintain itself.
A 2024 systematic review in Microorganisms of 13 next-generation sequencing studies found that PPI use "significantly affects the composition of the gut microbiota" across multiple studies. The mechanism identified was the translocation of oral bacteria into the gut via gastric acid suppression creating a consistent pattern of dysbiosis across PPI users. View source
Effect 3
This is the effect that keeps most people on PPIs for longer than they intended. When omeprazole suppresses acid production, the body responds by upregulating the number of proton pumps, a compensatory mechanism to counteract the suppression. The result is that when the PPI is stopped, the stomach can temporarily produce significantly more acid than it did before treatment began.
This rebound effect formally called rebound acid hypersecretion can cause symptoms that are worse than the original problem: intense heartburn, burning, and oesophageal discomfort. For many people, this feels like confirmation that they cannot manage without the medication. They restart it. The cycle continues.
The NHS Hertfordshire and West Essex Integrated Care Board has explicitly acknowledged this: research has found that people who have taken PPIs for more than two months may experience rebound acid when stopping, typically lasting up to two weeks. What it does not address is that for people who have been on PPIs for years, the rebound can be more prolonged and more disruptive.
Effect 4
Stomach acid is the gut's primary defence against pathogens bacteria, viruses, and parasites that enter the body through food and water. By dramatically reducing acid, PPIs lower this defence barrier. Research has consistently linked long-term PPI use with an increased risk of gut infections, including Clostridioides difficile (C. diff), Salmonella, and Campylobacter.
C. difficile infection is particularly significant. It is a serious gut infection that causes severe diarrhoea, is difficult to treat, and has a high recurrence rate. The NHS lists it explicitly as a known risk of long-term omeprazole use. The mechanism is well understood: without adequate acid, C. difficile spores that would ordinarily be destroyed in the stomach are able to colonise the intestine.
The risk is not dramatic in absolute terms most PPI users will never develop a serious gut infection. But the risk is real, it increases with duration of use, and it is worth understanding when making decisions about long-term PPI management.
Effect 5
This is not a side effect in the traditional sense, it is an absence. Omeprazole does not interact with, repair, or support the gut lining. It reduces acid output. That is all it does.
For many people, the underlying reason their gut became irritated and acidic in the first place was a compromised mucosal layer, the protective lining that insulates the stomach wall from acid. Gastritis, in particular, involves inflammation and thinning of this mucosal layer. Reducing the acid that irritates the exposed wall reduces symptoms. But the wall itself, and the mucosal layer above it, are unchanged.
This is why so many people find that the moment they stop omeprazole or even reduce the dose everything returns. The foundation was never worked on. The structure was quietened, not addressed.
What people commonly do to support their gut alongside PPI use
It is important to be clear about what this section is and what it is not. This is not a protocol for stopping omeprazole. Stopping a prescribed medication is a decision that should involve your GP, made with medical supervision and a structured tapering plan if appropriate. What follows is an overview of what many people explore to support their gut health during or after a period of PPI use, with their doctor's awareness.
With that clearly stated, the following approaches are commonly discussed and explored by people who are working with their doctors on gut health while taking or tapering PPIs:
None of these replace medical management. All of them are more effective when combined with, rather than substituted for, appropriate medical care. The goal is not to avoid medication, it is to give the gut the foundation it needs so that dependency on medication long term is not the only option.